Editas Medicine (EDIT) Chardan Genetic Medicines Conference summary

Company overview and strategic pillars

• Focuses on gene editing with foundational Cas9 and Cas12 patents, enabling broad applicability and non-dilutive capital through licensing deals.

• Three main pillars: reni-cel for sickle cell disease, in vivo gene editing, and IP/business development.

• Recent deals with Vertex, Vor Bio, Bristol Myers, and others support ongoing and future licensing opportunities.

Reni-cel program and clinical data

• Presented data on 18 sickle cell and 7 beta thalassemia patients, all sickle cell patients remained VOE-free post-treatment.

• Achieved normal total hemoglobin levels (~14 g/dL), addressing anemia and improving patient quality of life.

• Demonstrated robust, fast engraftment (mean 23 days) and efficient apheresis cycles (mean of 2).

• Plans to share more patient data and longer follow-up by year-end, tracking endpoints like VOEs and hemoglobin.

Commercial outlook and market dynamics

• Expects slow initial launch due to complex contracting and center readiness, but anticipates acceleration as processes standardize.

• Patient awareness and education boosted by recent competitor approvals, aiding trial enrollment.

• Intends to partner for ex-US commercialization due to cost and risk, focusing internal efforts on US market.

• Sees room for multiple products in the rare disease space, with gradual patient uptake expected.